Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roivant SciencesFRA:87S +2.26%51 Piotroski F-Score is 1 as of Aug. 11, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates FRA:87S with a GF Score™ of 51/100 and a GF Value™ of €2.51 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,325 Biotechnology companies, Roivant Sciences ranks worse than 91.4% on this metric.
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Roivant Sciences has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Roivant Sciences's Piotroski F-Score or its related term are showing as below:
FRA:87S'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 6
Current: 1
During the past 6 years, the highest Piotroski F-Score of Roivant Sciences was 6. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Roivant Sciences Piotroski F-Score Related Terms
Roivant Sciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:87S vs RPRX, INCY, INSM: Piotroski F-Score Comparison
For the Biotechnology subindustry, Roivant Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Roivant Sciences's current Net Income (TTM) was -226.48.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Roivant Sciences's return on assets of this year was -0.05190561. Roivant Sciences's return on assets of last year was -0.07129424.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Roivant Sciences's gearing of this year was 0.01813221. Roivant Sciences's gearing of last year was 0.01474203.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Roivant Sciences's current ratio of this year was 16.72086429. Roivant Sciences's current ratio of last year was 40.53661798.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Roivant Sciences's number of shares in issue this year was 720.777. Roivant Sciences's number of shares in issue last year was 680.287.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Roivant Sciences's gross margin of this year was 0.81225876. Roivant Sciences's gross margin of last year was 0.96376643.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Roivant Sciences's asset turnover of this year was 0.00148444. Roivant Sciences's asset turnover of last year was 0.00356691.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
0
+
0
+
0
+
0
+
0
=
1
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Roivant Sciences has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
Roivant Sciences (FRA:87S) has a Piotroski F-Score of 1 as of Aug. 11, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Roivant Sciences and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Roivant Sciences' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Roivant Sciences ranks #1211 out of 1325 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Roivant Sciences' Piotroski F-Score too high?
Roivant Sciences' current Piotroski F-Score of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Roivant Sciences' value of 1 is 66.7% below this industry median. Based on the distribution chart, Roivant Sciences ranks #1211 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Piotroski F-Score compare to RPRX and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #1211 out of 1325 companies for Piotroski F-Score. This places Roivant Sciences in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Roivant Sciences' value of 1 is 66.7% below this benchmark. Historically, Roivant Sciences' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Roivant Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,325 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Piotroski F-Score of 1 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Piotroski F-Score is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.51, compared to a current price of €30.79 — trading 1126.7% above its estimated fair value. The current Piotroski F-Score is 1, which is 67% below median its 10-year median of 3.00 and 66.7% below the Biotechnology industry median of 3.00. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current Piotroski F-Score is 1 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (FRA:87S) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of €30.79 is trading 1126.7% above its estimated GF Value™ of €2.51.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for FRA:87S:
Piotroski F-Score: 1 (67% below median its 10-year median of 3.00)
GF Value™: €2.51 vs. price of €30.79 (1126.7% above fair value)
Industry Position: 66.7% below the Biotechnology median (#1211 of 1325)
No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for FRA:87S
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87S has been successfully added to your 
